- PR Newswire•5 hours agoDexcom announces publication of key study in the Journal of the American Medical Association (JAMA) demonstrating the value of CGM in reducing A1C and hypoglycemia in diabetes patients on injection therapy
SAN DIEGO, Jan. 24, 2017 /PRNewswire/ -- Dexcom announces the first and only randomized, controlled study focusing solely on the benefit of continuous glucose monitoring (CGM) for diabetes patients on multiple daily injections (MDI) insulin therapy. The DIaMonD study (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes) is the first-of-its-kind study that demonstrates the impact of CGM on A1C and hypoglycemia in participants on a multiple daily injection insulin regimen.
- Business Wire•yesterdayDexCom Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017 at 4:30 p.m. Eastern Time
DexCom, Inc. today announced that it plans to release its fourth quarter and full year 2016 financial results after market close on Tuesday, February 28, 2017. Management will hold a conference call to review the company's fourth quarter and full year 2016 performance starting at 4:30 p.m.
- TheStreet.com•4 days ago
Health care companies Alcobra, Array and DexCom were in focus ahead of market open.
DXCM : Summary for DexCom, Inc. - Yahoo Finance
DexCom, Inc. (DXCM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||77.59 x 300|
|Ask||79.75 x 400|
|Day's Range||76.30 - 80.05|
|52 Week Range||47.92 - 96.38|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-116.59|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|